We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current 0RGI market cap is 2.23B. The company's latest EPS is EUR 0.9819 and P/E is 129.24.
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 64.67M | 63.25M | 66.8M | 65.89M | 103.99M |
| Operating Income | -22.07M | -17.37M | 1.96M | 28.3M | 28.06M |
| Net Income | -18.11M | -24.42M | -7.9M | 21.67M | 17.23M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 625.69M | 585.16M | 596.16M | 805.56M | 759.59M |
| Total Liabilities | 180.83M | 191.43M | 196.04M | 292.88M | 295.8M |
| Total Equity | 444.85M | 393.73M | 400.13M | 512.68M | 463.79M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -10.16M | -18.85M | 12.99M | 12.61M | 33.23M |
| Investing | -71.78M | -48.69M | 75.45M | 24.86M | 1.69M |
| Financing | 144.39M | -34.46M | -11.88M | -27.25M | -46.13M |
| Market Cap | 2.23B |
| Price to Earnings Ratio | 129.24 |
| Price to Sales Ratio | 21.41 |
| Price to Cash Ratio | 11.98 |
| Price to Book Ratio | 4.8 |
| Dividend Yield | - |
| Shares Outstanding | 17.54M |
| Average Volume (1 week) | 1.41k |
| Average Volume (1 Month) | 3.23k |
| 52 Week Change | 0.00% |
| 52 Week High | 126.90 |
| 52 Week Low | 126.90 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Cosmo Pharmaceuticals Nv |
| Address |
riverside ii dublin 20020 |
| Website | https://www.cosmopharmaceuticals.com |
| Industry | medicinal chems,botanicl pds (2833) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
